# Pomerantz LLP Opens Securities Fraud Investigation Into Rafael Holdings After 34.98% Stock Drop

> Pomerantz LLP is investigating Rafael Holdings for possible securities fraud after its Phase 3 Niemann-Pick study missed its endpoint and shares fell 34.98% to $1.32.

- Published: 2026-11-03T22:46:15+00:00
- Section: Legal & Disputes
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-03/pomerantz-rafael-holdings-securities-investigation
- Source: [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-3-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-rafael-holdings-inc-rfl)

## Key takeaways

- Pomerantz LLP is investigating whether Rafael Holdings and its officers or directors engaged in securities fraud or other unlawful business practices.
- Rafael Holdings said its Phase 3 TransportNPC study of Trappsol Cyclo in 94 patients did not achieve statistical significance on the primary endpoint.
- Rafael Holdings shares fell $0.71, or 34.98%, to close at $1.32 on September 30, 2026.
- Rafael Holdings submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) on October 29, 2026.

[Pomerantz LLP](https://akta.pro/company-profiles/0004jpx/pomerantz-llp) is investigating securities fraud claims on behalf of investors of [Rafael Holdings](https://akta.pro/company-profiles/0003tz6/rafael-holdings), Inc. (NYSE: RFL), the firm said in a November 3, 2026 announcement. The [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-3-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-rafael-holdings-inc-rfl) published the alert. The investigation concerns whether Rafael Holdings and certain of its officers or directors engaged in securities fraud or other unlawful business practices.

## Pomerantz's Rafael Holdings Investigation

Pomerantz LLP is a plaintiff-side securities litigation law firm founded in 1936 that represents investors in securities class actions, corporate governance cases and global investor recovery proceedings, according to akta.pro [company records](https://akta.pro/company-data). The firm directs Rafael Holdings investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation follows Rafael Holdings' September 30, 2026 press release announcing topline efficacy and safety data from its Cyclo Therapeutics, LLC subsidiary's pivotal Phase 3 TransportNPC study (CTD-TCNPC-301). The study evaluated Trappsol Cyclo (intravenous hydroxypropyl-β-cyclodextrin) in 94 patients diagnosed with Niemann-Pick Disease Type C. The press release said the result did not achieve statistical significance on the primary endpoint.

Rafael Holdings' stock price fell $0.71 per share, or 34.98%, to close at $1.32 per share on September 30, 2026. On October 29, 2026, Rafael Holdings submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) to treat Niemann-Pick Disease Type C, [Stock Titan](https://akta.pro/news-signals) reported. The Phase 3 study missed its primary endpoint but showed a 64% relative slowing of disease progression versus placebo, with serious adverse events more frequent.

## Pomerantz's Litigation Track Record

Pomerantz LLP maintains a global network of offices across New York, Chicago, Los Angeles, London, Paris and Tel Aviv, according to company records. The firm's historic recoveries include $3 billion for investors in the Petrobras securities litigation, $350 million for United Healthcare investors and $225 million for Comverse Technology investors.

## Earlier Pomerantz Investor Alerts

Pomerantz LLP announced a proposed class action settlement for purchasers of Gritstone bio securities on September 28, 2026, with a hearing set for December 4, 2026 and a $6 million settlement fund, PR Newswire reported. On September 1, 2026, the firm announced a class action lawsuit against Taboola.com Ltd. over alleged securities fraud, FinancialContent Business Page reported. Pomerantz announced on August 25, 2026 that a class action lawsuit had been filed against GPGI, Inc. alleging securities fraud or unlawful business practices, FinancialContent Business Page reported.

## Rafael Holdings' Conference Appearance

Rafael Holdings will host a fireside chat and one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, Stock Titan reported.

## Companies in this story

- [Pomerantz LLP company profile](https://akta.pro/company-profiles/0004jpx/pomerantz-llp) · website: http://pomerantzlaw.com
- [Rafael Holdings company profile](https://akta.pro/company-profiles/0003tz6/rafael-holdings) · website: https://rafaelholdings.com

---
News for Agent · https://newsforagent.com/llms.txt